Philip E. Thorpe - Concepedia

Author

Philip E. Thorpe

The University of Texas Southwestern Medical Center

Also Known As

P E Thorpe, P Thorpe, PHILIP E. THORPE, PHILIP THORPE, Philip E Thorpe, Philip E. THORPE, Philip E. Thorpe, Philip Thorpe, Thorpe, Philip E.

193

Publications

12.9K

Citations

H-Index

122

Concepts

All Affiliations

The University of Texas Southwestern Medical Center The Honourable Society of Lincoln's Inn Southwestern Medical Center Cancer Research UK

About

Philip E. Thorpe is an author at The University of Texas Southwestern Medical Center specializing in medicine, immunology, and tumor microenvironment.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	36	58	8.3K
2	Allergy	10	10	778
3	Natural Sciences	8	8	1.1K
4	Engineering	5	5	439
5	Health Sciences	4	4	604

Philip E. Thorpe

102

Publications

11.4K

Citations

H-Index

Page 1

	Year	Citations
Matrix metalloproteinase-9 triggers the angiogenic switch during carcinogenesis Gabriele Bergers, Rolf A. Brekken, Gerald McMahon, Nature Cell Biology Tumor BiologyAngiogenesisMatrix Metalloproteinase-9 TriggersPathologyVascular Biology	2000	2.8K
Increased exposure of anionic phospholipids on the surface of tumor blood vessels. Sophia Ran, Amber Downes, Philip E. Thorpe PubMed ApoptosisImmunologyPathologyCell DeathTumor Biology	2002	479
Tumor Infarction in Mice by Antibody-Directed Targeting of Tissue Factor to Tumor Vasculature Xianming Huang, Grietje Molema, Steven King, Science Antibody-directed TargetingEndothelial CellsSelective OcclusionImmunologyImmunoediting	1997	478
Up-regulation of endoglin on vascular endothelial cells in human solid tumors: implications for diagnosis and therapy. Francis Burrows, Elaine J. Derbyshire, Pier Luigi Tazzari, PubMed Endothelial CellsImmunologyEndoglin ExpressionHuman Solid TumorsTumor Biology	1995	336
Soluble Eph A receptors inhibit tumor angiogenesis and progression in vivo Dana M. Brantley, Nikki Cheng, Erin J Thompson, Oncogene AngiogenesisMedicineImmunologyVascular BiologyNeovascularization	2002	316
Selective inhibition of vascular endothelial growth factor (VEGF) receptor 2 (KDR/Flk-1) activity by a monoclonal anti-VEGF antibody blocks tumor growth in mice. Rolf A. Brekken, Jay Overholser, Victor Stastny, PubMed Receptor 2Vegf Receptor 2ImmunologyTumor BiologyAngiogenesis	2000	311
Phosphatidylserine is a marker of tumor vasculature and a potential target for cancer imaging and therapy Sophia Ran, Philip E. Thorpe International Journal of Radiation OncologyBiologyPhysics Oncologic ImagingMolecular ImagingPathologyTumor VasculaturePotential Target	2002	276
A Naturally Occurring Soluble Form of Vascular Endothelial Growth Factor Receptor 2 Detected in Mouse and Human Plasma John M.L. Ebos, Guido Bocci, Shan Man, Molecular Cancer Research	2004	209
New coupling agents for the synthesis of immunotoxins containing a hindered disulfide bond with improved stability in vivo. Philip E. Thorpe, Philip M. Wallace, Phillip P. Knowles, PubMed ImmunotoxicologyDisulfide LinkageImproved StabilityImmunologyHindered Disulfide Bond	1987	204
Targeting inside-out phosphatidylserine as a therapeutic strategy for viral diseases Melina Soares, Steven W. King, Philip E. Thorpe Nature Medicine Inside-out PhosphatidylserineSynthetic VirologyAntiviral Drug DevelopmentVirologyViral Structural Protein	2008	196

Page 1